Document Detail

Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
MedLine Citation:
PMID:  23108916     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of dabigatran are freedom from monitoring and less interaction with other drugs and food. It is ideal for patients who are unwilling to adhere to regular coagulation monitoring or whose therapeutic effect using warfarin is not optimal despite adequate monitoring and management. However, the impact of dabigatran on health-related quality of life (HRQoL) and drug compliance has been less evaluated. This study aimed to evaluate the clinical and humanistic outcomes of dabigatran use in Hong Kong.
HYPOTHESIS: Dabigatran 110 mg twice daily was non-inferior in stroke prophylaxis in AF patients compared to adjusted-dose warfarin; while dabigatran 150 mg twice daily was superior to adjusted-dose warfarin in the real world data in Hong Kong.
METHODS: We retrospectively analyzed 244 patients with newly diagnosed AF and prescribed dabigatran (n = 122) or warfarin (n = 122) for stroke prophylaxis from the Prince of Wales Hospital between January 2010 to November 2011. Clinical outcomes including death, stroke, bleeding, and HRQoL using the EuroQol EQ-5D-5L were compared between patients on dabigatran and warfarin.
RESULTS: The median duration of follow-up was 310 days. Stroke occurred in 2 patients (1.64%) in the dabigatran group and 4 in the warfarin group (3.28%) (adjusted hazard ratio [HR]: 0.53, P = 0.47). Bleeding of any degree occurred in 28 patients on dabigatran and 38 patients on warfarin (adjusted HR: 0.76, P = 0.28), with age over 70 years and renal impairment being significant positive predictors of bleeding (P = 0.01 and 0.02, respectively). Dyspepsia was the most common adverse event of dabigatran over warfarin (19.7% vs 8.2%, P = 0.01). Rate of discontinuation of dabigatran was 25.4%, with dyspepsia being the most common cause for discontinuation (6 patients, 4.92%). There was no significant difference in drug compliance or HRQoL at 1 year between the 2 groups (utility score 0.77 [dabigatran] vs 0.74 [warfarin], P = 0.28).
CONCLUSIONS: In Hong Kong, the clinical efficacy and safety of dabigatran were comparable to that of warfarin, and drug compliance and HRQoL of using dabigatran and warfarin were similar after 1 year of use.
Jason C S Ho; Andy M Chang; Bryan P Yan; Cheuk Man Yu; Yat Yin Lam; Vivian W Y Lee
Related Documents :
24023016 - Sevoflurane end-tidal to effect-site equilibration in women determined by response to l...
24016506 - Apixaban versus warfarin in patients with atrial fibrillation according to prior warfar...
12800726 - Accelerated intravenous rehydration.
25100236 - Suppressive effects of standard-dose rosuvastatin therapy on the progression of coronar...
20137966 - Long-term results after correction of persistent truncus arteriosus in 83 patients.
24785986 - A population-based analysis of contemporary rates of reoperation for penile prosthesis ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-10-25
Journal Detail:
Title:  Clinical cardiology     Volume:  35     ISSN:  1932-8737     ISO Abbreviation:  Clin Cardiol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  2013-04-26     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E40-5     Citation Subset:  IM    
Copyright Information:
© 2012 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antithrombins / adverse effects,  therapeutic use*
Atrial Fibrillation / complications*
Benzimidazoles / adverse effects,  therapeutic use*
Hong Kong
Quality of Life
Retrospective Studies
Stroke / prevention & control*
Warfarin / adverse effects,  therapeutic use*
beta-Alanine / adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Antithrombins; 0/Benzimidazoles; 11P2JDE17B/beta-Alanine; 5Q7ZVV76EI/Warfarin; I0VM4M70GC/dabigatran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Candida famata (Candida flareri).
Next Document:  Management of glioblastoma in an NF1 patient with moyamoya syndrome: a case report.